Open AccessCD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
Author(s) -
Elifcan Aladağ,
Halûk Demiroğlu,
Yahya Büyükaşık,
Mehmet Turğut,
Salih Aksu,
Nilgün Sayınalp,
İbrahim C. Haznedaroğlu,
Osman Özcebe,
Hakan Göker
Publication year - 2020
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.3906/sag-2001-173
Subject(s) - medicine , cd34 , melphalan , multiple myeloma , hematopoietic stem cell transplantation , transplantation , autologous stem cell transplantation , progenitor cell , haematopoiesis , stem cell , leukapheresis , surgery , absolute neutrophil count , urology , gastroenterology , chemotherapy , neutropenia , genetics , biology
High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106/kg. The aim of this study was to evaluate the relationship between the dose of CD34+HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.